Vaccine Design and Testing – Products

At the 2023 Grand Challenges Annual Meeting, Bill Gates, announced new investments to advance access to mRNA research and vaccine manufacturing technology that will support low- and middle-income countries.

Partnership between two Canadian life sciences leaders offers a commercial GMP manufacturing solution for Acuitas’ licensed partners developing promising next generation therapies.

This application note demonstrates the successful identification of two low-abundance monoclonal antibodies using next-generation protein sequencing.

Takara Bio Europe announced the launch of new High Quality grade mRNA production enzymes "T7 RNA polymerase, HQ" and "Pyrophosphatase (inorganic), HQ" suitable for pre-clinical and process development in mRNA vaccine and therapeutic manufacturing.

Learn more about influenza vaccine solutions!

The National Institutes of Health selected Exothera S.A. therapeutics to develop the manufacturing process for NIH’s intranasal vaccine against SARS-CoV-2.

New ready-to-ship xGen™ NGS solution will enable researchers to combat challenging diseases of today and prepare for the next pathogen of tomorrow.

Absolute Biotech has announced the reintroduction of SCICONS™ dsRNA antibodies, used to detect dsRNA intermediates of a wide range of viruses, including chikungunya, dengue, hepatitis, rabies, rhinovirus, polio and swine fever.

The Center for Emerging Viral Threats (CEVT) in Louisiana, USA, is using INTEGRA Biosciences’ liquid handling solutions for COVID-19 testing and viral genomics studies.

Meissa Vaccines announced it has entered into a manufacturing agreement with Exothera S.A. delivering customized process development and GMP manufacturing services for vaccines, viral vectors and nucleic acids.